

TODAY'S DATE _____ M M D D Y Y	Your confidential ID number is the first two letters of your FIRST name, the first two letters of your LAST name, the MONTH of your birth, and the DAY of your birth.	<table border="1"><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>FN</td><td>FN</td><td>LN</td><td>LN</td><td>M</td><td>M</td><td>D</td><td>D</td></tr></table> CONFIDENTIAL IDENTIFIER									FN	FN	LN	LN	M	M	D	D
FN	FN	LN	LN	M	M	D	D											

Attachments 9 & 10

Intensive Didactic Post-Course Evaluation Instrument

Word version and screenshot

Intensive Didactic Post-Course Evaluation

Public reporting burden of this collection of information is estimated to average 10 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA (0920-0995).

S1 How satisfied were you with your overall learning experience?

very unsatisfied ① ② ③ ④ ⑤ very satisfied

S2 How satisfied were you with the quality of the content?

very unsatisfied ○ ○ ○ ○ ○ very satisfied

S3 How satisfied were you with the trainer(s)?

very unsatisfied ○ ○ ○ ○ ○ very satisfied

S4 How satisfied were you with the teaching methods?

very unsatisfied ○ ○ ○ ○ ○ very satisfied

S5 What could improve this training?

CE1 Do you believe this activity was influenced by commercial interests?

- ① Yes
- ② No

CE2 Was this presentation evidence-based?

- ① Yes
- ② No

CE3a Were the learning objectives met?

- ① Yes
- ② No

CE3b If the learning objectives were not met, please explain,

A1 As a result of information presented, do you intend to make changes in your practice or at your worksite setting?

- ① Yes
- ② No
- ③ Not my job
- ④ I already use these practices
- ⑤ Other reason (please specify) _____

A2 If yes, please list at least one intended change.

CHLAMYDIA

LOC1bef How confident were you in your ability to describe how chlamydia infections present clinically, BEFORE the training?

not at all confident ① ② ③ ④ ⑤ very confident

LOC1aft How confident are you AFTER the training?

not at all confident very confident

LOC2bef How confident were you in your ability to describe the current CDC screening recommendations for chlamydia, including extra-genital screening BEFORE the training?

not at all confident very confident

LOC2aft How confident are you AFTER the training?

not at all confident very confident

LOC3bef How confident were you in your ability to obtain or instruct patients to collect the recommended specimens from indicated sites to diagnose chlamydia BEFORE the training?

not at all confident ① ② ③ ④ ⑤ very confident 77 NA

LOC3aft How confident are you AFTER the training?

not at all confident very confident NA

LOC4bef How confident were you in your ability to treat patients diagnosed with chlamydia and related anogenital syndromes based on the most current CDC treatment recommendations BEFORE the training?

not at all confident very confident NA

LOC4aft How confident are you AFTER the training?

not at all confident very confident NA

KC1 What is the CDC recommended regimen for treating asymptomatic uncomplicated chlamydia infection of the cervix, urethra, or rectum?

- Acyclovir 1 g twice a day for 7 days
- Azithromycin 1 g orally in a single dose or doxycycline 100 mg twice a day for 7 days
- Azithromycin 1 g orally in a single dose plus ceftriaxone 250 mg intramuscularly in a single dose
- Ciprofloxacin 500 mg orally in a single dose

KC2 What is the recommended follow-up for a non-pregnant patient after diagnosis and treatment of chlamydia?

- ① A test of cure at 2 weeks, and repeat test at 3 months
- ② A test of cure at 2 weeks, and repeat test at 12 months
- ③ Repeat test in 3 months

④ Repeat test in 12 months

PPC1bef Approximately what % of sexually active asymptomatic female patients under age 25 did you screen annually for chlamydia BEFORE this training?

0% 1-25% 26-50% 51-75% 76-90% >91% NA
 ① ② ③ ④ ⑤ ⑥ 77

PPC1aft What % do you intend to screen AFTER the training?

0% 1-25% 26-50% 51-75% 76-90% >91% NA

PPC2bef Approximately what % of pregnant patients under age 25 did you screen for chlamydia BEFORE this training?

0% 1-25% 26-50% 51-75% 76-90% >91% NA

PPC2aft What % do you intend to screen AFTER the training?

0% 1-25% 26-50% 51-75% 76-90% >91% NA

GONORRHEA

LOG1bef How confident were you in your ability to describe how gonorrhea infections present clinically BEFORE this training?

not at all confident very confident

LOG1aft How confident are you AFTER the training?

not at all confident very confident

LOG2bef How confident were you in your ability to describe the current CDC screening recommendations for gonorrhea, including extra-genital screening BEFORE this training?

not at all confident very confident

LOG2aft How confident are you AFTER the training?

not at all confident very confident

LOG3bef How confident were you in your ability to obtain or direct patients to collect the recommended specimens from indicated sites to diagnose gonorrhea BEFORE this training?

not at all confident ① ② ③ ④ ⑤ very confident 77 NA

LOG3aft How confident are you AFTER the training?

not at all confident very confident NA

LOG4bef How confident were you in your ability to treat patients with gonorrhea according to current CDC recommendations in light of antibiotic resistance in *N. gonorrhoeae* BEFORE this training?

not at all confident very confident NA

LOG4aft How confident are you AFTER the training?

not at all confident very confident NA

KG1 What is the CDC recommended treatment for a patient diagnosed with uncomplicated urethral, cervical, or rectal gonorrhea?

① Ceftriaxone 250 mg intramuscularly only

- ② Azithromycin 2 g orally in a single dose only
 ③ Ceftriaxone 250 mg intramuscularly plus azithromycin 1 g orally in a single dose
 ④ Cefixime 400 mg orally plus doxycycline 100 mg orally BID for 7 days

KG2 What is the recommended follow-up for a non-pregnant patient after diagnosis and treatment of gonorrhea?

- ① A test of cure at 2 weeks, and repeat test at 3 months
 ② A test of cure at 2 weeks, and repeat test at 12 months
 ③ Repeat test in 3 months
 ④ Repeat test in 12 months

PPG1bef Approximately what % of sexually active asymptomatic female patients under 25 did you screen annually for gonorrhea BEFORE this training?

0%	1-25%	26-50%	51-75%	76-90%	>91%	NA
<input type="radio"/> ①	<input type="radio"/> ②	<input type="radio"/> ③	<input type="radio"/> ④	<input type="radio"/> ⑤	<input type="radio"/> ⑥	77

PPG1aft What % do you intend to screen AFTER the training?

0%	1-25%	26-50%	51-75%	76-90%	>91%	NA
<input type="radio"/>						

PPG2bef Approximately what % of pregnant patients under age 25 did you screen for gonorrhea BEFORE this training?

0%	1-25%	26-50%	51-75%	76-90%	>91%	NA
<input type="radio"/>						

PPG2aft What % do you intend to screen AFTER the training?

0%	1-25%	26-50%	51-75%	76-90%	>91%	NA
<input type="radio"/>						

PPG3bef Approximately what % of sexually active male patients who have sex with men did you screen annually for urogenital and extragenital gonorrhea and chlamydia BEFORE this training?

0%	1-25%	26-50%	51-75%	76-90%	>91%	NA
<input type="radio"/>						

PPG3aft What % do you intend to screen AFTER the training?

0%	1-25%	26-50%	51-75%	76-90%	>91%	NA
<input type="radio"/>						

SYPHILIS

LOS1bef How confident were you in your ability to identify the stages of syphilis based on their clinical manifestations BEFORE this training?

not at all confident very confident

LOS1aft How confident are you AFTER the training?

not at all confident very confident

LOS2bef How confident were you in your ability to describe current CDC screening recommendations for syphilis BEFORE this training?

not at all confident very confident

LOS2aft How confident are you AFTER the training?

not at all confident very confident

S3bef How confident were you in your ability to order and interpret the CDC recommended serologic tests to diagnose syphilis BEFORE this training?

not at all confident ① ② ③ ④ ⑤ very confident 77 NA

LOS3aft How confident are you AFTER the training?

not at all confident very confident NA

LOS4bef How confident were you in your ability to clinically manage patients diagnosed with syphilis based on CDC treatment, follow-up, and partner management recommendations BEFORE this training?

not at all confident very confident NA

LOS4aft How confident are you AFTER the training?

not at all confident very confident NA

KS1 What is the CDC recommended regimen for treating primary and secondary syphilis in adults who are *not* HIV+ or pregnant?

- ① Acyclovir 1 g twice a day for 7 days
- ② Azithromycin 1 g orally in a single dose
- ③ **Benzathine penicillin G 2.4 million units IM in a single dose**
- ④ Benzathine-procaine penicillin 2.4 million units in a single dose

PPS1bef Approximately what % of your male patients who have sex with men did you screen at least once a year for syphilis BEFORE this training?

0% 1-25% 26-50% 51-75% 76-90% >91% NA

PPS1aft What % do you intend to screen AFTER the training?

0% 1-25% 26-50% 51-75% 76-90% >91% NA

PPS2bef Approximately what % of your pregnant patients did you screen for syphilis BEFORE this training?

0% 1-25% 26-50% 51-75% 76-90% >91% NA

PPS2aft What % do you intend to screen AFTER the training?

0% 1-25% 26-50% 51-75% 76-90% >91% NA

PPS3bef Approximately what % of your patients recently diagnosed with syphilis did you test for HIV BEFORE this training?

0% 1-25% 26-50% 51-75% 76-90% >91% NA

PPS3aft What % do you intend to screen AFTER the training?

0% 1-25% 26-50% 51-75% 76-90% >91% NA

HUMAN PAPILLOMAVIRUS (HPV)

LOHPV1bef How confident were you in your ability to describe the pathogenesis of genital HPV and identify it clinically BEFORE this training?

not at all confident very confident

LOHPV1aft How confident are you AFTER the training?
not at all confident very confident

LOHPV2bef How confident were you in your ability to describe the national cervical cancer screening recommendations, including HPV testing, BEFORE this training?
not at all confident very confident

LOHPV2aft How confident are you AFTER the training?
not at all confident very confident

LOHPV3bef How confident were you in your ability to treat genital warts BEFORE the training?
not at all confident ① ② ③ ④ ⑤ very confident 77 NA

LOHPV3aft How confident are you AFTER the training?
not at all confident very confident NA

LOHPV4bef How confident were you in your ability to describe CDC/ACIP recommendations for HPV vaccination BEFORE this training?
not at all confident very confident

LOHPV4aft How confident are you AFTER the training?
not at all confident very confident

PPHPV1bef With approximately what % of your non-vaccinated female patients ages 11 through 26 did you discuss HPV vaccination during a preventive health visit BEFORE this training?
0% 1-25% 26-50% 51-75% 76-90% >91% NA

PPHPV1aft With what % do you intend to discuss this AFTER the training?
0% 1-25% 26-50% 51-75% 76-90% >91% NA

PPHPV2bef With approximately what % of your non-vaccinated male patients ages 11 through 21 did you discuss HPV vaccination during a preventive health visit BEFORE this training?
0% 1-25% 26-50% 51-75% 76-90% >91% NA

PPHPV2aft With what % do you intend to discuss this AFTER the training?
0% 1-25% 26-50% 51-75% 76-90% >91% NA

PPHPV3bef With approximately what % of your non-vaccinated male patients age 26 or under who have sex with men or are HIV+ did you discuss HPV vaccination during a preventive health visit BEFORE this training?
0% 1-25% 26-50% 51-75% 76-90% >91% NA

PPHPV3aft With what % do you intend to discuss this AFTER the training?
0% 1-25% 26-50% 51-75% 76-90% >91% NA

LOSH1bef How confident were you in your ability to describe the major components (5 P's) of a routine sexual history BEFORE this training?

not at all confident very confident

LOSH1aft How confident are you AFTER the training?

not at all confident very confident

LOSH2bef How confident were you in your ability to demonstrate respectful, non-judgmental communication skills to discuss sexual practices, sexual risks, and risk reduction strategies with patients BEFORE this training?

not at all confident ① ② ③ ④ ⑤ very confident 77 NA

LOSH2aft How confident are you AFTER the training?

not at all confident very confident NA

PPSH1bef For approximately what % of patients older than 15 seeing you for a preventive health visit did you take a sexual history that asks about behaviors that could put them at risk of getting or transmitting an STD BEFORE this training?

0% 1-25% 26-50% 51-75% 76-90% >91% NA

PPSH1aft What % do you intend to ask about risk behaviors AFTER the training?

0% 1-25% 26-50% 51-75% 76-90% >91% NA

PPSH2bef For approximately what % of patients older than 15 seeing you for a preventive health visit did you take a sexual history that asked whether they had oral, vaginal, or anal sex BEFORE this training?

0% 1-25% 26-50% 51-75% 76-90% >91% NA

PPSH2aft What % do you intend to ask whether they had oral, vaginal, or anal sex AFTER the training?

0% 1-25% 26-50% 51-75% 76-90% >91% NA

EXPEDITED PARTNER THERAPY

EPT As a result of the information presented, do you intend to provide Expedited Partner Therapy (EPT) to heterosexual partners of those diagnosed with gonorrhea and/or chlamydia?

- ① Yes
- ② No
- ③ Not applicable to my practice or job
- ④ Not allowed in my state/practice
- ⑤ My practice/worksites is in the planning stages to offer EPT
- ⑥ My practice/worksites already offers EPT
- ⑦ EPT was not discussed